Prothena Q1 net loss $36.3M; PRX012 gets Fast Track, Phase 1 started

PROTHENA CORP PUBLIC LTD CO

2022-Q1 EPS reported -$0.78 revenue$1,153,000

Net loss of $36.3M ($0.78 per share) vs $36.7M loss ($0.91) in Q1 2021; revenue $1.2M.
Cash and restricted cash $544.3M at quarter end; no debt; net cash used in ops/investing $37.4M.
PRX012 initiated Phase 1 SAD study, received FDA Fast Track for Alzheimer's disease.
R&D expense $27.3M (up 29% YoY) driven by birtamimab, PRX012, PRX005 programs.
FY 2022 guidance: net cash outflow $120-132M, net loss $154-170M, year-end cash ~$454M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.